Influence of the lactose grade within dry powder formulations of fluticasone propionate and terbutaline sulphate

被引:17
|
作者
Le, V. N. P. [1 ]
Bierend, H. [2 ]
Robins, E. [3 ]
Steckel, H. [2 ]
Flament, M. P. [1 ]
机构
[1] Univ Lille Nord France, Coll Pharm, INSERM 1008, F-59006 Lille, France
[2] Univ Kiel, Inst Pharmaceut, D-24118 Kiel, Germany
[3] APTAR Pharma, F-27100 Le Vaudreuil, France
关键词
Dry powder inhalation; Lactose; Physicochemical properties; Adhesion; Aerodynamic behaviour; Inverse gas chromatography; INVERSE GAS-CHROMATOGRAPHY; SALBUTAMOL SULFATE; INHALATION FORMULATIONS; INTERACTIVE MIXTURES; SURFACE-ENERGY; IN-VITRO; PERFORMANCE; CARRIER; DISPERSION; FUNCTIONALITY;
D O I
10.1016/j.ijpharm.2011.10.030
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Dry powder formulations are often composed of fine drug particles and coarser carrier particles, typically alpha-lactose monohydrate. However, the performance of a powder formulation may be highly dependent on the lactose quality and source. This study investigated the characteristics of lactose that influence the drug-to-carrier interaction and the performance of lactose-based dry powder inhaler formulations. The selected lactoses differed in the preparation processes and the content of fine lactose particles. Efficiency testing was done using fluticasone propionate and terbutaline sulphate as model drugs. Inverse gas chromatography was used to determine the surface heterogeneity distribution of different energy sites of the lactose and to understand the mechanism by which the fine carrier particles can improve the performance of dry powder inhalers. To assess the adhesion of respirable-sized drug to carrier particles, a simple method was developed based on aspiration and considering the whole blend as it is used in dry powder inhalers. When the percentage of fine lactose is high, a lower quantity of drug adheres to the lactose and/or the adhesion force is also lower. This was confirmed by the aerosolization assays done in the TSI (twin stage impinger). A correlation was observed between adhesion characteristics and inertial impaction. For both drugs, the fine particle fractions were highest in blends that present a greater proportion of lactose fine particles. A fairly good correlation between the fine particle fractions of both drugs and the peak max value and the AUC (area under curve) were found by inverse gas chromatography. With higher fine particle fraction values, which correspond to higher content of fines, the peak maxima determined by inverse gas chromatography were shifted to higher adsorption potentials, which supports the agglomeration hypothesis. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:75 / 82
页数:8
相关论文
共 50 条
  • [21] LONG-TERM SAFETY OF FLUTICASONE PROPIONATE AND FLUTICASONE PROPIONATE/SALMETEROL MULTIDOSE DRY POWDER INHALERS IN ASTHMATIC PATIENTS
    Mansfield, L.
    Yiu, G.
    Sakov, A.
    Liu, S.
    Caracta, C.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2016, 117 (05) : S65 - S65
  • [22] Efficacy and safety of dry powder fluticasone propionate in children with persistent asthma
    LaForce, CF
    Pearlman, DS
    Ruff, ME
    Silvers, WS
    Weinstein, SW
    Clements, DS
    Brown, A
    Duke, S
    Harding, SM
    House, KW
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2000, 85 (05) : 407 - 415
  • [23] FLUTICASONE PROPIONATE AND FLUTICASONE/SALMETEROL MULTIDOSE DRY POWDER INHALERS COMPARED WITH PLACEBO FOR PERSISTENT ASTHMA
    Sher, L.
    Yiu, G.
    Sakov, A.
    Liu, S.
    Caracta, C.
    ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2016, 117 (05) : S61 - S62
  • [24] Influence of fine lactose and magnesium stearate on low dose dry powder inhaler formulations
    Guchardi, R.
    Frei, M.
    John, E.
    Kaerger, J. S.
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2008, 348 (1-2) : 10 - 17
  • [25] Pharmacokinetics, Safety, and Tolerability of a New Fluticasone Propionate Multidose Dry Powder Inhaler Compared With Fluticasone Propionate Diskus® in Healthy Adults
    Vutikullird, Apinya Bee
    Gillespie, Michael
    Song, Sharon
    Steinfeld, Jonathan
    JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY, 2016, 29 (02) : 207 - 214
  • [26] Can Pharmacokinetic Studies Assess the Pulmonary Fate of Dry Powder Inhaler Formulations of Fluticasone Propionate? (vol 23, 48, 2021)
    Hochhaus, Gunther
    Chen, Mong-Jen
    Kurumaddali, Abhinav
    Schilling, Uta
    Jiao, Yuanyuan
    Drescher, Stefanie K.
    Amini, Elham
    Berger, Simon M.
    Kandala, Bhargava
    Tabulov, Christine
    Shao, Jie
    Seay, Brandon
    Abu-Hasan, Mutasim N.
    Baumstein, Sandra M.
    Winner, Lawrence
    Shur, Jagdeep
    Price, Robert
    Hindle, Michael
    Wei, Xiangyin
    Carrasco, Cynthia
    Sandell, Dennis
    Oguntimein, Oluwamurewa
    Kinjo, Minori
    Delvadia, Renishkumar
    Saluja, Bhawana
    Lee, Sau L.
    Conti, Denise S.
    Bulitta, Jurgen B.
    AAPS JOURNAL, 2021, 24 (01):
  • [27] Dry Powder Inhalers: Study of the Parameters Influencing Adhesion and Dispersion of Fluticasone Propionate
    Le, V. N. P.
    Thi, T. H. Hoang
    Robins, E.
    Flament, M. P.
    AAPS PHARMSCITECH, 2012, 13 (02): : 477 - 484
  • [28] Dry Powder Inhalers: Study of the Parameters Influencing Adhesion and Dispersion of Fluticasone Propionate
    V. N. P. Le
    T. H. Hoang Thi
    E. Robins
    M. P. Flament
    AAPS PharmSciTech, 2012, 13 : 477 - 484
  • [29] Influence of size and surface roughness of large lactose carrier particles in dry powder inhaler formulations
    Donovan, Martin J.
    Smyth, Hugh D. C.
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2010, 402 (1-2) : 1 - 9
  • [30] Nanoparticle agglomerates of fluticasone propionate in combination with albuterol sulfate as dry powder aerosols
    El-Gendy, Nashwa
    Pornputtapitak, Warangkana
    Berkland, Cory
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2011, 44 (04) : 522 - 533